TRACT Therapeutics Announces Partnership with Taiwan Bio Therapeutics
Successful Transfer of Regulatory T Cell Therapy Platform
Collaboration Aims to Advance Organ Transplant Outcomes
Taipei, Taiwan and Chicago, IL – Business Wire – Taiwan Bio Therapeutics Inc. (TWSE:4174) and TRACT Therapeutics are pleased to announce the successful transfer of TRACT's regulatory T cell (Treg) therapy platform to Taiwan Bio Therapeutics.
TRACT's Treg therapy platform is a novel approach to organ transplantation that has the potential to revolutionize the field.
The platform is based on the discovery that Tregs play a key role in regulating the immune response to transplanted organs. By manipulating Tregs, it is possible to prevent the rejection of transplanted organs and improve long-term outcomes for patients.
The transfer of TRACT's Treg therapy platform to Taiwan Bio Therapeutics will enable the company to further develop and commercialize this promising new technology.
Taiwan Bio Therapeutics is a leading biotechnology company with a strong track record of developing and commercializing innovative new therapies.
The company is well-positioned to bring TRACT's Treg therapy platform to market and make a significant impact on the lives of patients.
Benefits of TRACT's Regulatory T Cell Therapy Platform
- Prevents the rejection of transplanted organs
- Improves long-term outcomes for patients
- Has the potential to revolutionize the field of organ transplantation
About Taiwan Bio Therapeutics Inc.
Taiwan Bio Therapeutics Inc. is a leading biotechnology company focused on the development and commercialization of innovative new therapies for unmet medical needs.
The company's mission is to improve the lives of patients by providing them with access to safe and effective new treatments.
Taiwan Bio Therapeutics is headquartered in Taipei, Taiwan.
About TRACT Therapeutics
TRACT Therapeutics is a clinical-stage biopharmaceutical company developing novel Treg-based therapies for the treatment of autoimmune and inflammatory diseases.
The company's lead product candidate, TRACT-01, is a humanized monoclonal antibody that targets the CD80 molecule on the surface of Tregs.
TRACT-01 is designed to selectively expand and activate Tregs, thereby restoring immune balance and reducing inflammation.
TRACT Therapeutics is headquartered in Chicago, IL.
Comments